This morning, Moberg Pharma and Karo Healthcare announced an expansion of their licensing agreement ...
A more supportive jackpot environment should drive a visible acceleration in ZEAL's Q2 billings.
Redeye is positive on the news flow over the past week, highlighting that Senzime continues to stren...
Redeye comments on the terms in Annexin’s rights issue and recent newsflow, which includes updates f...
Markets have rewarded our recent conviction. In this update, we trim one position back to 5%, taking...
Redsense Medical levererade en omsättningstillväxt om 34 procent till 6,4 MSEK och ett positivt röre...
The FDA has accepted Xbrane's BLA resubmission for Lucamzi and set a BsUFA action date of 29 October...
• Considering the alternatives in wound treatment • Discussions about investigator-initiated studies...
Sprint Bioscience intar en speciell roll inom svensk läkemedelsutveckling.
DO & CO looks set to report solid Q4 results on June 11.
During the quarter, Acenta continued executing on previously signed agreements and took the first st...
Scandinavian ChemoTech announced a 6MSEK growth loan from a major Swedish financial institution.
Redeye briefly comments on Cinclus’ announcement that patient screening has been successfully comple...
Yesterday, LION provided an update on the developments in its mobility segment - specifically the tr...
As a follow-up to our initial comment, Redeye updates its estimates and valuation model following ye...
Redeye comments on the outcome of Elicera’s rights issue.
Dellia redovisade en nettoomsättning om 214,4 MNOK (121,6) i Q1'26, motsvarande en tillväxt om 76,4 ...
Sivers has announced a strategic collaboration with GlobalFoundries (GF), under which Sivers' laser ...
Redeye provides its Q1 2026 sector update for Nordics serial acquirers.
Genovis announced after market close the acquisition of KPL, a Danish company with a proprietary rec...
